• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors.

作者信息

Broekkamp C L, De Graaf J S, van Delft A M

机构信息

Scientific Development Group, Organon International B.V., Pharma Division Akzo, Oss, The Netherlands.

出版信息

Arzneimittelforschung. 1990 May;40(5):544-9.

PMID:1974432
Abstract

trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepinol[4,5-c]pyrrolidine maleate (Org 5222) is a new compound with effects on animal behaviour indicating strong antipsychotic potential based on antagonism of dopaminergic and serotonergic effects. The compound inhibits apomorphine-induced climbing behaviour, mouse locomotor activity, rat activity in an open field, shuttle box behaviour in rats, pergolide induced circling in 6-hydroxydopamine(6-OHDA) lesioned rats, serotonin agonist-induced forepaw treading, head shakes and penile erections. The compound is less effective in inducing catalepsy, and antagonising SKF-38393 (tetrahydro- 1-phenyl-1H-3-benzazepine-7,8-diol HCl)-induced circling in 6-OHDA-lesioned rats and it does not induce perioral movements in rats. Based on these data and the neurochemical profile of the compound it was decided that this compound merits clinical investigation in a programme aiming for an effective antipsychotic agent with reduced risks of extrapyramidal side-effects.

摘要

相似文献

1
Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors.
Arzneimittelforschung. 1990 May;40(5):544-9.
2
Neurochemical studies with the potential antipsychotic compound trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate.
Arzneimittelforschung. 1990 May;40(5):550-4.
3
Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum.血清素能药物对氟哌啶醇诱导的大鼠纹状体多巴胺D2受体上调的影响。
Eur J Pharmacol. 1997 Feb 26;321(2):163-9. doi: 10.1016/s0014-2999(96)00948-x.
4
Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate.
Arzneimittelforschung. 1990 May;40(5):536-9.
5
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.S 16924((R)-2-[1-[2-(2,3-二氢-苯并[1,4]二氧杂环己烯-5-基氧基)-乙基]-吡咯烷-3-基]-1-(4-氟-苯基)-乙酮),一种具有显著5-羟色胺(5-HT)1A激动剂特性的新型潜在抗精神病药物:II. 与氯氮平和氟哌啶醇相比的功能概况。
J Pharmacol Exp Ther. 1998 Sep;286(3):1356-73.
6
Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.多巴胺D-1和D-2受体在阿扑吗啡、SK&F 38393、培高利特和LY 171555诱导的6-羟基多巴胺损伤大鼠的转圈行为中的差异参与。
Psychopharmacology (Berl). 1985;85(3):346-52. doi: 10.1007/BF00428200.
7
Biotransformation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-H-dibenz[2,3:6,7]oxepin o [4,5-c]pyrrolidine maleate in rats.
Arzneimittelforschung. 1990 May;40(5):540-4.
8
PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.PD 158771,一种具有D2/D3部分激动剂和5-羟色胺(1A)激动剂作用的潜在抗精神病药物。II. 临床前行为效应。
Neuropharmacology. 2000 Apr 27;39(7):1211-21. doi: 10.1016/s0028-3908(99)00214-2.
9
In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).4-(4-氟亚苄基)-1-[2-[5-(4-氟苯基)-1H-吡唑-4-基]乙基]哌啶(NRA0161)的体外和体内药理学特征
Life Sci. 2002 Oct 18;71(22):2603-15. doi: 10.1016/s0024-3205(02)02085-4.
10
Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions.多巴胺D-1和D-2拮抗剂对单侧6-羟基多巴胺损伤大鼠中多巴胺激动剂诱导的转圈行为的差异性抑制作用。
Eur J Pharmacol. 1984 Jul 13;102(2):349-54. doi: 10.1016/0014-2999(84)90267-x.

引用本文的文献

1
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.帕金森病动物模型:新型治疗方法的来源和疾病病因的线索。
Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x.
2
Evaluation of the clinical efficacy of asenapine in schizophrenia.评价阿塞那平治疗精神分裂症的临床疗效。
Expert Opin Pharmacother. 2010 Aug;11(12):2107-15. doi: 10.1517/14656566.2010.506188.
3
Asenapine.阿塞那平
Nat Rev Drug Discov. 2009 Nov;8(11):843-4. doi: 10.1038/nrd3027.
4
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.阿塞那平可提高皮质多巴胺、去甲肾上腺素和5-羟色胺的释放。有证据表明,皮质和皮质下多巴胺系统通过不同机制被激活。
Psychopharmacology (Berl). 2009 Jun;204(2):251-64. doi: 10.1007/s00213-008-1456-5. Epub 2009 Feb 7.
5
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.阿塞那平,一种新型精神药理药物:精神分裂症临床疗效的临床前证据。
Psychopharmacology (Berl). 2008 Feb;196(3):417-29. doi: 10.1007/s00213-007-0973-y. Epub 2007 Oct 17.
6
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability.僵住症作为一种用于检测具有锥体外系副作用倾向的抗精神病药物的啮齿动物模型。
Psychopharmacology (Berl). 1995 Jul;120(2):128-33. doi: 10.1007/BF02246184.
7
The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine.嗅结节作为非典型抗精神病药物在爪试验中的作用部位:利培酮、丙硫喷地、ORG 5222、舍吲哚和奥氮平的作用
Psychopharmacology (Berl). 1995 Jun;119(4):428-39. doi: 10.1007/BF02245859.